This paper focuses on medical insurance drug negotiations in China and the United States, conducting a comparative analysis from five dimensions of the background and entities involved in negotiations, the scope of drug selection, the measurement of drug value, the negotiation process, and the outcomes of negotiations. It delves into the similarities and differences in medical insurance drug negotiations between China and the United States, providing an important perspective for further understanding the differences in drug price regulation between the two countries' healthcare security systems. This study holds both theoretical and practical significance.
Key words
medical insurance drug negotiations /
comparative analysis /
the United States
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 吕兰婷,姜来,刘文凤,等.美国高昂药品价格形成的原因及其启示[J].中华医院管理杂志, 2022,38(9):712-716.
[2] 117th US Congress.Inflation Reduction Act of2022[EB/OL].(2022-08-16)[2025-01-01].https://www.congress.gov/bill/117th-congress/house-bill/5376/text.
[3] Centers for Medicare & Medicaid Services.Medicare drug price negotiation[EB/OL].(2023-06-30)[2025-01-04].https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation.
[4] 胡善联.中美药价谈判思路迥异[N/OL].(2024-02-02)[2025-01-01].https://www.yyjjb.com.cn/yyjjb/202402/202402021610291029_17858.shtml.
[5] Centers for Medicare & Medicaid Services.Medicare drug price negotiation program: negotiated prices for initial price applicability year 2026[EB/OL].(2024-08-15)[2025-01-02].https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026.
[6] U.S.Department of Health and Human Services.HHS selects the first drugs for Medicare drug price negotiation[EB/OL].(2023-08-29)[2024-12-02].https://public3.pagefreezer.com/browse/HHS.gov/02-01-2024T03:56/https://www.hhs.gov/about/news/2023/08/29/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html.
[7] 国家医疗保障局.关于公布《2024年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案》及申报指南等文件的公告[EB/OL].(2024-06-28)[2025-01-01].https://www.nhsa.gov.cn/art/2024/6/28/art_109_13084.html.
[8] PADULA W V, KOLCHINSKY P.Can generalized cost-effectiveness analysis leverage meaningful use of novel value elements in pharmacoeconomics to inform Medicare drug price negotiation?[J].Value in health, 2024, 27(8): 1100-1107.
[9] O'BRIEN J M, HANSEN J E.Section 50 of the inflation reduction act drug price negotiation program: considerations for the Centers for Medicare & Medicaid Services, manufacturers, and the health economics and outcomes research community[J].Value in health, 2023, 26(12): 1681-1685.
[10] SULLIVAN S D, HERNANDEZ I, RAMSEY S D, et al.Has the Centers for Medicare & Medicaid services implicitly adopted a value framework for Medicare drug price negotiations?[J].Value in health, 2023, 26(12): 1686-1688.
[11] SULLIVAN S D.Medicare drug price negotiation in the United States: implications and unanswered questions[J].Value in health, 2023, 26(3): 394-399.
[12] 官海静,陶立波,韩晟.创新药价格形成与医保准入的影响因素分析[J].中国医疗保险,2024(6):15-20.
[13] GOSTIN L O, HODGE J G J R, TWINAMATSIKO A J.Medicare's historic prescription drug price negotiations[J].JAMA, 2023, 330(17): 1621-1622.
[14] 中华人民共和国人力资源和社会保障部.关于将36种药品纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的通知[EB/OL].(2017-07-13)[2024-11-02].https://www.mohrss.gov.cn/SYrlzyhshbzb/shehuibaozhang/zcwj/yiliao/201707/t20170718_274153.html.
[15] 胡善联.中国医保药品价格谈判回顾和展望[J].卫生经济研究,2024,41(1):9-13.
[16] 国家医疗保障局,人力资源社会保障部.关于印发《国家基本医疗保险、工伤保险和生育保险药品目录(2024年)》的通知[EB/OL].(2024-11-28)[2025-01-02].https://www.nhsa.gov.cn/art/2024/11/28/art_104_14886.html.
[17] 摩熵医药.《中药行业现状与未来趋势白皮书》[EB/OL].(2024-07-22)[2024-12-22].https://www.pharnexcloud.com/zixun/sd_8164.
[18] JAKSA A, ARENA P J.The potential role of real-world evidence in Centers for Medicare & Medicaid Services' future price negotiations: recommendations for a robust framework[J].Journal of managed care & specialty pharmacy, 2024, 30(6): 604-607.
